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Obesity commonly leads to hepatic steatosis, which often provokes lipotoxic injuries to hepatocytes that cause nonalcoholic steato-
hepatitis (NASH). NASH, in turn, is associated with the accumulation of insoluble protein aggregates that are composed of ubiqui-
tinated proteins and ubiquitin adaptor p62/sequestosome 1 (SQSTM1). Formation of p62 inclusions in hepatocytes is the critical
marker that distinguishes simple fatty liver from NASH and predicts a poor prognostic outcome for subsequent liver carcinogenesis.
However, the molecular mechanism by which lipotoxicity induces protein aggregation is currently unknown. Here, we show that,
upon saturated fatty acid-induced lipotoxicity, TANK binding kinase 1 (TBK1) is activated and phosphorylates p62. TBK1-
mediated p62 phosphorylation is important for lipotoxicity-induced aggregation of ubiquitinated proteins and formation of large
protein inclusions in hepatocytes. In addition, cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING),
upstream regulators of TBK1, are involved in lipotoxic activation of TBK1 and subsequent p62 phosphorylation in hepatocytes.
Furthermore, TBK1 inhibition prevented formation of ubiquitin-p62 aggregates not only in cultured hepatocytes, but also in
mouse models of obesity and NASH. Conclusion: These results suggest that lipotoxic activation of TBK1 and subsequent p62 phos-
phorylation are critical steps in the NASH pathology of protein inclusion accumulation in hepatocytes. This mechanism can pro-
vide an explanation for how hypernutrition and obesity promote the development of severe liver pathologies, such as steatohepatitis
and liver cancer, by facilitating the formation of p62 inclusions. (HEPATOLOGY 2018; 68:1331-1346).
I
ncidence of obesity and its corresponding compli-
cations are increasing at an alarming rate.(1) Non-
alcoholic fatty liver disease (NAFLD) is among
many abnormalities associated with obesity and, in
many patients, progresses to nonalcoholic steatohepati-
tis (NASH).(2) Although the precise molecular events
involved in the development of NASH remain uncer-
tain, it has been proposed that obesity-induced
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elevation in plasma free fatty acid levels provokes lipo-
toxic injuries to cells in the liver.(2) Saturated fatty acids
(SFAs) are major perpetrators of lipotoxic injuries to
cells, whereas unsaturated fatty acids (UFAs) often
confer protection against SFA-induced lipotoxicity.
NASH is characterized by various consequences of lip-
otoxic injury to liver cells, such as hepatocyte balloon-
ing, protein inclusion formation, ectopic cell death,
inflammation, and fibrosis.(3-5) Obesity and NASH
are also established risk factors for hepatocellular carci-
noma (HCC).(6)
Formation of insoluble protein inclusions in hepato-
cytes is characteristic of a damaged liver for both mice
and humans.(3-5,7-9) These inclusions are also the criti-
cal marker that distinguishes simple NAFLD from
NASH(7,9) and consist primarily of ubiquitinated pro-
teins such as keratins (KRT8/18) and the ubiquitin
adaptor, p62/sequestosome 1 (SQSTM1).(3,8) Hepatic
protein inclusions are closely linked to lipotoxic injuries
and metabolic pathologies because they are frequently
associated with fat droplet accumulation.(7) The mouse
model of NASH, associated with large protein inclu-
sions, is established by inducing obesity with a high-fat
diet (HFD) and administering additional insults that
provoke inflammation, such as choline deficiency,(10,11)
transgenic gene modulation,(5,12) or hepatotoxin
administration.(5) However, HFD-induced obesity per
se is also sufficient to induce protein aggregates of
ubiquitinated proteins and p62 that are insoluble in
nonionic detergents.(13-15) Although these findings
suggest a causal link between obesity and hepatic pro-
tein aggregates, we currently have a very limited under-
standing of how obesity-associated lipotoxicity
promotes the formation of insoluble protein inclusions.
Acquiring this understanding is important, especially
because p62 accumulation in hepatocytes was recently
demonstrated to facilitate obesity-associated liver
fibrosis and HCC development.(12,16)
To investigate the mechanism of how protein
aggregates are formed in NASH, we established an
in vitro model in which SFAs, such as palmitic acid
(PA) and stearic acid (SA), prominently induce
insoluble inclusion bodies consisting of ubiquitinated
proteins and p62 in the cytoplasm of human hepa-
toma HepG2 cells.(15) Using this system, as well as
in vivo mouse models, we showed that attenuation
of autophagic flux is one of the major causes of pro-
tein aggregate formation. In hepatocytes, obesity and
SFA-induced lipotoxicity induce a prolonged eleva-
tion in cytosolic calcium, which interferes with the
fusion between autophagosomes and lysosomes.(15)
Interestingly, several stress signaling pathways, such
as endoplasmic reticulum (ER) stress, oxidative
stress, c-Jun N-terminal kinase, and p53 pathways,
were not significantly involved in this protein inclu-
sion process.(15)
Although autophagy inhibition may explain how
protein inclusions can be formed upon lipotoxic
injury, we observed that protein aggregates induced
by simple autophagy inhibition were morphologically
distinct from SFA- or obesity-induced protein inclu-
sions. This histomorphological discrepancy suggests
that additional unknown pathways may mediate the
formation of hepatic protein inclusions. Here, using
both cultured cells and animal models of lipotoxicity
and obesity, we show that a signaling pathway lead-
ing to TANK binding kinase 1; TBK1 activation
induces phosphorylation and aggregation of p62,
which facilitates the lipotoxicity-induced formation
of ubiquitinated protein inclusions. Because inhibi-
tion of the TBK1 pathway effectively and specifically
attenuates ubiquitin-p62 protein inclusions and
fibrotic liver pathologies, this pathway could be a
promising target for the treatment of NASH or
other diseases associated with autophagy defects and
proteinopathy.
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HepG2 cells were obtained from ATCC (HB-8065).
Primary hepatocytes were isolated and cultured as
described.(17) To induce lipotoxicity, de-lipidated low-
endotoxin bovine serum albumin (BSA) was loaded
with PA and other fatty acids, as described,(15,17) and
applied to cultured cells. Details in cell-culture proce-
dures are described in the Supporting Information.
ANIMAL STUDIES
Mice of C57BL/6 genetic background were used for
this study. All animal studies were ethically approved and
overseen by the University Committee onUse and Care of
Animals at the University of Michigan (Ann Arbor, MI).
Details in animal procedures, including mouse genotypes
and their sources, number, age and sex of mice, diet treat-
ment, and drug administration, are described in the Sup-
porting Information and corresponding figure legends.
QUANTIFICATION AND
STATISTICAL ANALYSIS
Immunoblotting images were quantified by densitom-
etry, and protein expressions are expressed as relative
band intensities. Colocalization of different proteins was
expressed as line-scan evaluation graph or Pearson’s coef-
ficient. All the statistical analyses were performed with
more than three independent biological replicates (n  3)
for cell-culture studies or with the indicated numbers of
animals for in vivo mouse studies. Statistical significance
of differences between two groups was calculated using a
Student t test (*P< 0.05; **P < 0.01; ***P < 0.001).
OTHER METHODS
For details of reagents, lentiviral constructs, subcel-
lular fractionation, protein analysis, immunocytochem-
istry, and histology, see the Supporting Information.
Results
SFA INDUCES LARGE p62/SQSTM1
INCLUSIONSWHILEOTHER
AUTOPHAGY INHIBITORS DONOT
We and others have formerly shown that thapsigar-
gin (Tg), bafilomycin A1 (Baf), and SFA interfere
with autophagic flux, mainly through elevation of
cytosolic calcium and subsequent inhibition of
autophagosomal-lysosomal fusion.(15,18,19) However,
we noticed that the patterns of p62 inclusions formed
from SFA-induced lipotoxicity are apparently distinct
from what we observed in Tg- and Baf-treated human
hepatoma HepG2 cells. PA-induced protein aggre-
gates appear as rod-shaped sizable inclusions in
the cytoplasm (Fig. 1A), similar to hepatic protein
inclusions observed during NASH(4) and NASH-
associated HCC,(12) whereas Tg- or Baf-induced p62
aggregates are observed as numerous small puncta
(Fig. 1A). This obvious difference suggests that, in
addition to modulating the calcium signaling, lipotoxic
insults modulate unknown target(s) that control the
morphology of the p62-ubiquitin inclusion bodies.
The protein inclusions found in NASH are called
Mallory-Denk bodies, which consist mainly of ubiquiti-
nated KRT8/18 and p62.(3,8) Although we knew that
the SFA-induced protein aggregates in HepG2 cells are
enriched with p62 and ubiquitinated proteins (Fig. 1A-
D),(20) we wanted to identify which specific proteins are
found in this protein inclusion. Therefore, we isolated
insoluble protein fractions from control and PA-treated
cells, and subjected them to sodium dodecyl sulfate
(SDS)/polyacrylamide gel electrophoresis and Coomas-
sie staining (Supporting Fig. S1A). Then, we searched
for protein bands that were specifically enriched in PA-
treated cells. From this analysis, we identified a 54-
kDa band as one of the most prominently enriched
bands in the insoluble fraction from the PA-treated cells
(Supporting Fig. S1A). Tandem mass spectrometry
analysis revealed that this band corresponds to KRT8
(Supporting Fig. S1A), supporting the close relationship
between our PA-induced protein inclusions and the
Mallory-Denk bodies. Therefore, this SFA-induced lip-
otoxicity model provides a pathophysiologically relevant
experimental system for modeling NASH-associated
protein inclusions.
SFA INDUCES PHOSPHORYLATION
OF p62 AT SERINE 403
p62 proteins accumulated under SFA-induced lipo-
toxicity exhibited strong electrophoretic mobility retarda-
tion (band shift; Fig. 1B), suggesting posttranslational
modification of the protein. Although the calcium-
channel blocker, verapamil, strongly suppressed p62 accu-
mulation by restoring autophagic flux,(15) it did not
inhibit the p62 band shift (Fig. 1B), suggesting that this
modification is not controlled by calcium-autophagy
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FIG. 1. SFA-induced lipotoxicity provokes p62/SQSTM1 phosphorylation in insoluble inclusion bodies. HepG2 cells were treated
with BSA (Con), PA (500 lM), Tg (1 lM), Baf (100 nM), or PA 1 verapamil (0.1, 1, or 10 lM) for 9 hours and subjected to the
following analyses. (A,B) Cells were subjected to immunostaining (A) and immunoblotting (B). Arrows indicate band shifts of p62.
(C) PA-untreated (Con) and -treated cell lysates were subjected to immunoprecipitation (IP) using anti-p62 antibody or control
immunoglobulin G (IgG). IP complex and whole-cell lysates were analyzed by immunoblotting. Background nonspecific and IgG
chain bands were identified from p62 and ubiquitin blots, respectively, and used as loading controls. Arrows indicate positions of
shifted (black) and unshifted (gray) p62 bands. (D) Cells were subjected to serial protein extraction (solubility fractionation) with indi-
cated concentration of Triton X-100 (TX100) or SDS and analyzed by immunoblotting with indicated antibodies (left panel) and
quantified (right panels). (E,F) Cells were subjected to immunostaining with indicated antibodies (upper panels) and analyzed by line-
scan evaluation of each signal across protein inclusions (lower panels). DNA was stained with 40,6-diamidino-2-phenylindole (blue).
Boxed areas in fluorescence images are magnified in rightmost panels. Scale bars, 5 lm. Quantification data are shown as mean 6
SEM. ***P < 0.001 (Student t test). Arrowheads indicate the exact or nearest position of the protein molecular-weight markers (kD).
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signaling. To identify the nature of this modification, we
immunoprecipitated p62 from SFA-treated cells and
analyzed the protein with antibodies that detect various
posttranslational modifications.
Ubiquitination and acetylation signals were not
detected in the region corresponding to p62 bands
(Fig. 1C), but we did find a strong phosphorylation
signal on Ser403 of p62 after SFA treatment (Fig.
1C). This corresponded to the shifted p62 bands (Fig.
1C). The gel shift was reduced by treatment with both
lambda protein phosphatase and calf intestinal phos-
phatase (Supporting Fig. S1B). Phosphorylated p62
was almost exclusively found in insoluble fractions
(Fig. 1D) and colocalized with the protein inclusions
consisting of p62 (Fig. 1E) and ubiquitinated proteins
(Fig. 1F). SFA-induced p62 shift and phosphorylation
was also prominently observed in freshly isolated pri-
mary mouse hepatocytes (Supporting Fig. S1C).
Autophagy inhibition and subsequent p62 accumula-
tion can promote casein kinase 2 (CK2)-dependent p62
phosphorylation at Ser403.(21) Autophagy inhibitors Tg
and Baf, however, produced very weak p62 Ser403 phos-
phorylation, in contrast to the strong p62 phosphoryla-
tion induced upon SFA treatment (Supporting Fig.
S1D,E). Tetrabromobenzotriazole, a specific inhibitor of
CK2,(21) did not inhibit SFA-induced p62 phosphoryla-
tion (Supporting Fig. S1F). These results indicate that
neither autophagy inhibition nor CK2 is primarily
responsible for SFA-induced p62 phosphorylation. Con-
sistent with this, SFA-induced p62 phosphorylation
occurred earlier than its total protein accumulation
(Supporting Fig. S1G), suggesting that this phosphoryla-
tion is not simply attributed to increased protein accumu-
lation and is likely an active process.
TBK1 IS ACTIVATED UPON
SFA TREATMENT
We then tested whether TBK1, another p62 Ser403
kinase,(22) is responsible for SFA-induced p62 phosphor-
ylation. SFA strongly activated TBK1 in HepG2 cells
(Fig. 2A), as monitored by activation loop phosphoryla-
tion (Ser172) of TBK1. In contrast to SFA, Tg and Baf
only induced moderate activation of TBK1 (Fig. 2A),
consistent with the p62 phosphorylation results (Support-
ing Fig. S1D,E). Calcium-channel blockers verapamil
and nicardipine did not inhibit SFA-induced TBK1
phosphorylation (Fig. 2B), although they strongly
reduced p62 accumulation (Figs. 1B and 2B) by restoring
autophagic flux.(15) Interestingly, UFAs, such as oleic
acid (OA) and docosahexaenoic acid (DHA), almost
completely inhibited the action of SFA in activating
TBK1 (Fig. 2C) and inducing p62 phosphorylation and
accumulation (Fig. 2D).
In cells, activated TBK1 (p-TBK1) colocalized with
phosphorylated p62 (p-p62; Fig. 2E) and total p62
(Fig. 2F) inclusions, suggesting that TBK1 may be the
kinase responsible for Ser403 phosphorylation of p62.
However, unlike p-p62 that was predominantly found
in the insoluble fraction (Fig. 1D), p-TBK1 was found
in both soluble and insoluble fractions (Supporting
Fig. S1H). One possibility is that TBK1 is present at
the soluble side of the protein inclusion in order to effi-
ciently phosphorylate p62 and assemble them into the
insoluble inclusions. Consistent with this idea, PA-
activated TBK1 phosphorylated p62 in an in vitro
kinase assay (Supporting Fig. S1I) and can bind to
endogenous p62 in reciprocal coimmunoprecipitation
assays (Supporting Fig. S1J).
TBK1 IS REQUIRED FOR SFA-
INDUCED p62 PHOSPHORYLATION
AND ACCUMULATION
We were curious whether TBK1 actively promoted
p62 phosphorylation and formation of ubiquitin-p62
aggregates in this lipotoxic context. Therefore, we used
two recently discovered pharmacological inhibitors for
TBK1: BX795(23) and amlexanox.(24) Both BX795 and
amlexanox effectively suppressed SFA-induced p62
phosphorylation (Fig. 3A), supporting the hypothesis
that TBK1 mediates the effect of SFA on p62 phos-
phorylation. Interestingly, SFA-induced accumulation
of p62 and ubiquitinated proteins in insoluble fractions
(Fig. 3A) and cytoplasmic inclusions (Fig. 3B) were also
strongly inhibited, suggesting a relationship between
p62 phosphorylation and protein inclusion formation.
Although BX795 and amlexanox are relatively spe-
cific inhibitors for TBK1, they may also inhibit other
kinases such as phosphoinositide-dependent kinase 1
and inhibitory jB kinase e.(23,24) To independently
examine the role of TBK1, we used TBK1-specific
short hairpin RNA (shRNA) constructs. shRNA-
mediated silencing of TBK1 almost completely inhib-
ited the SFA-stimulated phosphorylation of p62 (Fig.
3C), indicating that TBK1 is indeed the major kinase
that phosphorylates p62 in response to SFA. TBK1
silencing also prevented accumulation of insoluble p62
and ubiquitinated proteins (Fig. 3C), suggesting that
the TBK1 activation and subsequent phosphorylation
of p62 is responsible for accumulation of insoluble pro-
tein aggregates in SFA-treated cells.
5133
CHO, PARK, ET AL.Hepatology, Vol. 68, No. 4, 2018 
THE CYCLIC GMP-AMP
SYNTHASE/STIMULATOR
OF INTERFERON GENES AXIS
IS REQUIRED FOR SFA-INDUCED
TBK1 ACTIVATION
Next, we explored the mechanism of how TBK1 is
activated upon lipotoxic insult during obesity. We
focused on stimulator of interferon genes (stimulator
of interferon genes [STING]), a physiological activator
of TBK1.(25) Unstimulated STING resides in the ER
membrane, while upon stimulation with foreign DNA
or cyclic dinucleotides, it translocates into an unknown
cytoplasmic compartment where it interacts with
TBK1 and induces TBK1 activation.(25) Notably, lipid
composition of the ER membrane is dramatically
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FIG. 2. SFA induces TBK1 activation and aggregation with phosphorylated p62. HepG2 cells were treated with BSA (Con), PA
(500 lM), Tg (1 lM), Baf (100 nM), tunicamycin (Tm; 5 lg/mL), verapamil (Ver; 50 lM), nicardipine (Nic; 100 lM), SA (500
lM), OA (500 lM), and/or DHA (500 lM) for 9 hours, followed by immunoblotting (A-D), immunoblotting quantification (C,D;
lower panels), and immunostaining (E,F). Immunostained images of PA-treated cells (upper panels) were analyzed by line-scan evalu-
ation of each signal across protein inclusions (lower panels). Scale bars, 5 lm. Quantification data are shown as mean 6 SEM. **P <
0.01 (Student t test). Arrowheads indicate the exact or nearest position of the protein molecular-weight markers (kD).
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altered during SFA-induced lipotoxicity,(26) and lipid
modification (palmitoylation) of STING is required
for its activation.(27) Under SFA-induced lipotoxicity,
STING was found to colocalize with p-TBK1 (Fig.
4A), and shRNA-mediated silencing of STING sub-
stantially decreased SFA-induced TBK1 activation
(Fig. 4A,B and Supporting Fig. S2A,B). STING
silencing was also sufficient to prevent SFA-induced
p62 phosphorylation and ubiquitin-p62 inclusions
(Fig. 4B and Supporting Fig. S2A-D), supporting the
idea that the STING-TBK1 axis mediates SFA-
induced p62 phosphorylation and aggregation in
hepatocytes.
Cyclic GMP-AMP (cGAMP), an upstream regulator
of STING, can be synthesized in animal cells by the
action of cGAMP synthase (cGAS). cGAS is activated
by the presence of cytoplasmic DNA, which could result
from viral infection(28) or mitochondrial collapse.(29,30)
Importantly, lipotoxic damage and NASH are associated
with mitochondrial dysfunction and cytoplasmic leakage
of mitochondrial DNA,(31,32) which can activate cGAS
and subsequently the STING-TBK1 axis. Indeed,
shRNA-mediated silencing of cGAS decreased SFA-
induced TBK1 activation (Fig. 4C,D). cGAS silencing
also inhibited p62 phosphorylation (Fig. 4D and Sup-
porting Fig. S3A,B), STING translocation to the p-
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FIG. 3. TBK1 mediates SFA-induced p62 phosphorylation and aggregation into ubiquitinated protein inclusions. (A,B) HepG2 cells
were treated with BSA (Con), PA (500 lM), BSA 1 BX795 (20 lM), PA 1 BX795, BSA 1 Amlexanox (Amx; 100 lM), or PA
1 Amx for 9 hours. (A) Cells were lysed, fractionated into 1% Triton X-100-soluble and -insoluble fractions, and then subjected to
immunoblotting (left panels) and immunoblotting quantification (right panels). (B) Cells with indicated treatments were subjected to
immunostaining (upper panel). Boxed areas in fluorescence images are magnified in rightmost panels. Amount of aggregated proteins
was quantified (lower panel). Scale bars, 5 lm. (C) HepG2 cells were transduced with shRNA lentiviruses targeting luciferase (sh-
Con) or TBK1 (sh-TBK1 #1 and #2) and incubated for 48 hours. Then, cells were treated with BSA or PA (500 lM) for 9 hours,
followed by subcellular fractionation, immunoblotting (upper panel), and immunoblotting quantification (lower panels). TBK1 was
analyzed from soluble fractions while p62, ubiquitin, and b-actin were analyzed from insoluble fractions. All data are shown as mean
6 SEM. **P < 0.01; ***P < 0.001 (Student t test). Arrowheads indicate the exact or nearest position of the protein molecular-weight
markers (kD).
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TBK1-positive compartment (Supporting Fig. S3C,D),
and accumulation of ubiquitin-p62 inclusions (Fig. 4C,D
and Supporting Fig. S3A-D). These results indicate that
cGAS is necessary for SFA-induced activation of the
STING-TBK1 axis and subsequent p62 phosphorylation
and aggregation.
Although cGAS activation is necessary for activat-
ing the TBK1 axis during SFA-induced lipotoxicity, it
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FIG. 4. The cGAS-STING axis mediates SFA-induced activation of TBK1. At 48 hours after infection with shRNA lentiviruses for
luciferase (sh-Con), STING (sh-STING), or cGAS (sh-cGAS#1 and #2), HepG2 cells were treated with BSA (Con) or PA (500
lM) for 9 hours. Then, cells were subjected to immunostaining (A,C), subcellular fractionation and immunoblotting (B,D; left pan-
els), and immunoblotting quantification (B,D; right panels). Boxed areas in fluorescence images are magnified in rightmost panels.
Immunostained images of PA-treated control cells (A, upper panel) were analyzed by line-scan evaluation of each signal across protein
inclusions (A, lower panel). Scale bars, 5 lm. Quantification data are shown as mean 6 SEM. *P < 0.05; **P < 0.01 (Student t test).
Arrowheads indicate the exact or nearest position of the protein molecular-weight markers (kD).
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was not sufficient for inducing p62 inclusion. For
instance, TBK1 activation by extracellular cGAMP(28)
(Supporting Fig. S4A) did not provoke p62 phosphor-
ylation and accumulation in cells (Supporting Fig.
S4B). Therefore, activation of additional SFA-induced
signaling pathways seems to be necessary for TBK1 to
properly induce p62 phosphorylation and aggregation.
We tested whether the requirement of STING and
cGAS for activating the TBK1-p62 axis could be repli-
cated in primary mouse hepatocytes, using Sting- and
cGas-knockout mice.(28) As observed in HepG2 cells,
PA-induced lipotoxicity in wild-type (WT) mouse
hepatocytes triggered strong phosphorylation of TBK1
(Supporting Fig. S5A) and p62 (Supporting Fig. S5B)
in protein inclusions. However, primary hepatocytes
isolated from Sting- and cGas-knockout mice exhibited
dramatic attenuation of these processes in both immu-
nostaining (Supporting Fig. S5A,B) and immunoblot-
ting (Supporting Fig. S5C-F) experiments. These
results support the requirement of the cGAS-STING
axis in lipotoxicity-induced TBK1 activation and




FACTOR 2 TARGETS AND
AUTOPHAGIC FLUX
Excessive accumulation of p62 can up-regulate the
nuclear factor erythroid 2-related factor 2 (Nrf2) tran-
scription factor because p62 inhibits Kelch-like ECH-
associated protein 1, an Nrf2 suppressor.(33) SQSTM1,
the gene encoding p62, is also a transcriptional target
of Nrf2; therefore, p62 accumulation leads to further
up-regulation of p62 expression, forming a positive
feedback loop.(33) Consistent with this pathway, SFA
induced strong expression of Nrf2 target genes, includ-
ing SRX, NQO1, GSTA1, and SQSTM1 (Supporting
Fig. S6A-D). Silencing of cGAS, STING, or TBK1
abolished the lipotoxicity-induced Nrf2 target gene
expression (Supporting Fig. S6A-D), whereas silenc-
ing of p62/SQSTM1 did not inhibit lipotoxicity-
induced TBK1 activation (Supporting Fig. S6E).
These results indicate that, in the context of lipotoxic-
ity, TBK1 acts as an upstream regulator of p62 and
other Nrf2 target genes.
As we formerly reported,(15) PA-induced lipotoxic-
ity provoked an almost complete segregation between
an autophagosome marker, microtubule-associated
protein light chain 3 (LC3), and a lysosomal marker,
lysosome-associated membrane protein 1 (LAMP1;
Supporting Fig. S7A,B), indicating a strong autophagy
arrest at the autophagosomal-lysosomal fusion step.
TBK1 inhibitors, BX795 and amlexanox, were able to
substantially restore the colocalization between LC3
and LAMP1 (Supporting Fig. S7A,B), indicating that
they can, at least partially, resume autophagic flux dur-
ing lipotoxicity. As a result of efficient lysosomal fusion
and subsequent degradation, the level of LC3-positive
autophagosomes was reduced by the TBK1 inhibitors
(Supporting Fig. S7C). It is possible that reduced p62
expression and aggregation during TBK1 inhibition
may have lessened the autophagy overload and thereby
alleviated the autophagic defects. Restoration of auto-
phagic flux may have further contributed to efficient
elimination of p62 and ubiquitinated protein inclu-
sions (Fig. 3) as a positive feedback.
TBK1 INHIBITION SUPPRESSES
PROTEIN INCLUSIONS IN LIVERS
OF OBESE MICE
Next, we examined whether TBK1 is important
for p62 control in vivo during HFD-induced fatty
liver.(13-15) As observed in SFA-treated HepG2 cells,
insoluble p62 induced by HFD was phosphorylated at
Ser403 (Fig. 5A). Ten days of TBK1 inhibition by
BX795 administration was sufficient to reduce this
phosphorylation, suggesting a mechanistic role of
TBK1 in HFD-induced p62 phosphorylation (Fig.
5A). The level of p62 and ubiquitinated proteins in
hepatic inclusion bodies was also dramatically reduced
to the level of preobese conditions (Fig. 5A,B), indicat-
ing that TBK1 is indeed important for p62 regulation
during obesity. However, BX795 was also found to sub-
stantially reduce body weight without altering food
intake (Supporting Fig. S8A,B). Because systemic
TBK1 inhibition is known to control energy metabo-
lism and inflammation through adipose tissues,(24,34) it
is possible that these inhibitors corrected the HFD-
induced protein inclusion pathologies indirectly through
suppression of obesity and normalization of metabolism.
To address this issue, we generated liver-specific
TBK1-knockout (L-Tbk1-KO) mice by crossing
Tbk1F/F mice with the Albumin-Cre strain. As expected,
L-Tbk1-KO mice exhibited dramatically reduced
expression of both p-TBK1 and TBK1 in liver tissue
(Fig. 5C). However, HFD-induced body weight gain
was almost the same between L-Tbk1-KO mice and L-
Tbk1-WT (Tbk1F/F; littermate control) mice (Support-
ing Fig. S8C,D), suggesting that the effect of liver-
9133
CHO, PARK, ET AL.Hepatology, Vol. 68, No. 4, 2018 
specific TBK1 loss on general metabolism is minimal.
Then, we analyzed the effect of L-Tbk1-KO on hepatic
protein inclusions. Despite the minimal effects on obe-
sity development (Supporting Fig. S8C,D), liver-
specific TBK1 deletion dramatically reduced p62 phos-
phorylation (Fig. 5C), as well as accumulation of p62
and ubiquitinated proteins in insoluble inclusion bodies
(Fig. 5C,D). These results demonstrate that TBK1 is
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FIG. 5. Inhibition of TBK1 suppresses p62 phosphorylation and accumulation in livers of obese mice. (A,B) Four-month-old
C57BL/6 male mice kept on HFD for 2 months were subjected to daily administration of phosphate-buffered saline (Con; n 5 7) or
BX795 (25 mg/kg body weight, intraperitoneal; n 5 6) for 10 days. LFD-kept mice (n 5 5) of the same age were used as a negative
control. (C,D) Five-month-old littermate-controlled Tbk1F/F (n516) and Albumin-Cre/Tbk1F/F (n516) male mice of C57BL/6 back-
ground, kept on HFD for 3 months, were analyzed. (A,C) Livers were subjected to solubility fractionation. One percent Triton X-
100-soluble and -insoluble fractions were analyzed by immunoblotting and immunoblotting quantification. (B,D) Liver sections were
subjected to p62 immunostaining. Hematoxylin counterstaining was used to visualize nuclei. Boxed areas in top panels are magnified
in bottom panels. Scale bars, 200 lm. All data are shown as mean 6 SEM. *P < 0.05; **P < 0.01; ***P < 0.001 (Student t test).
Arrowheads indicate the exact or nearest position of the protein molecular-weight markers (kD).
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indeed critical for obesity-induced p62 phosphorylation
and subsequent formation of ubiquitin-p62 inclusions.
TBK1 INHIBITION REDUCES
p62 INCLUSIONS AND LIVER
FIBROSIS DURING NASH
Although HFD induces modest p62 inclusion for-
mation (Fig. 5A,B),(13-15) HFD feeding in WT mice
did not produce typical NASH pathologies such as
active steatohepatitis or fibrotic lesions.(17) Therefore,
HFD is combined with additional insults, such as
nutritional deficiency(10,11) or expression of foreign
proteins,(5,12) to induce a stronger NASH phenotype.
These NASH models often produce much stronger
accumulation of p62 and ubiquitinated proteins when
compared to the simple HFD model.(5) Therefore, we
tested the role of TBK1 in a more severe NASH
model, induced by a methionine-restricted choline-
deficient (CD)-HFD,(11) which recapitulates many of
the human NASH pathologies.(11) These include
severe hepatosteatosis and liver fibrosis (Supporting
Fig. S9A), attenuated weight gain (Supporting Fig.
S9B), and extensive liver damage (Supporting Fig.
S9C). These pathologies were strongly suppressed by
dietary supplementation of choline and methionine
(CS-HFD; Supporting Fig. S9A-C).
We found that this CD-HFD model produced
much stronger accumulation of phosphorylated p62
proteins (Fig. 6A), compared to the low-fat diet
(LFD) or CS-HFD control animals (Supporting Fig.
S9D). Correspondingly, accumulation of p62 and
ubiquitinated proteins was also very pronounced in the
CD-HFD model (Fig. 6A and Supporting Fig. S9D).
As observed in the simple HFD model (Fig. 5A), a
10-day treatment of the TBK1 inhibitor, BX795, was
sufficient to suppress p62 phosphorylation and accu-
mulation, as well as ubiquitinated protein inclusions
(Fig. 6A) in the CD-HFD model. In this case, reduc-
tion in p62 inclusions was not associated with any sig-
nificant changes in body weight (Supporting Fig. S9E)
or level of hepatic fat accumulation (Fig. 6B and Sup-
porting Fig. S9F). Levels of liver damage (Fig. 6C),
hepatocyte cell death (Fig. 6D and Supporting Fig.
S9F), and hepatic macrophage infiltration (Fig. 6D,E)
were also comparable between BX795-untreated and -
treated groups.
However, interestingly, we found that CD-HFD-
induced expression of inflammatory cytokines, such as
TNF1, interleukin (IL) 6 and IL10, was substantially
suppressed by BX795 treatment (Supporting Fig.
S9G). Furthermore, level of liver fibrosis, monitored
through Sirius Red staining (Fig. 7A,B) and a-smooth
muscle actin (a-SMA) expression (Fig. 7A-E), was
substantially reduced by the BX795 treatment. Other
markers of liver fibrosis, such as collagen (COL) levels
(COL1A1 and COL3A1) and profibrogenic markers
of hepatic stellate cells (e.g., matrix metalloproteinases
[MMPs], tissue inhibitors of metalloproteinase
[TIMPs], lysyl oxidase [LOX], connective tissue
growth factor [CTGF], and platelet endothelial cell
adhesion molecule 1 [PECAM-1]), were also induced






Suppression of TBK1 and subsequent inhibition of
p62 protein inclusions (Fig. 6A,B) did not alleviate
liver damage and hepatocyte death (Fig. 6C,D). How-
ever, given that TBK1 inhibition strongly reduced
fibrotic pathologies (Fig. 7A-E), it is still possible that
hepatic p62 protein inclusions somehow contribute to
fibrotic pathologies by inducing sublethal damages in
hepatocytes. One such hepatocyte-originated signal is
reactive oxygen species (ROS) that provoke hepatic
stellate cell activation.(35,36) Indeed, in a recent report,
hepatocyte-specific knockout of p62, which inhibits
protein inclusion formation, strongly suppressed ROS
accumulation and fibrosis during NASH.(12) We
tested whether TBK1 inhibition, which suppresses
p62 inclusion (Fig. 6A,B), can also reduce ROS accu-
mulation during CD-HFD-induced NASH. ROS
visualization using dihydroethidium (DHE) revealed
that, as expected, CD-HFD prominently up-regulated
liver ROS level, whereas BX795 treatment strongly
antagonized the effect of CD-HFD (Fig. 8A,B).
Therefore, TBK1 inhibition effectively suppressed




We then tested the genetic involvement of the
cGAS-STING pathway in the mouse NASH models.
Upon the simple HFD treatment, Sting-KO mice pro-
duced less p62 phosphorylation and accumulation
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when compared to WT mice (Supporting Fig. S10A,
B) without significant effects on obesity development
(Supporting Fig. S10D,E). Accumulation of ubiquiti-
nated proteins was also much less pronounced in
Sting-KO mice (Supporting Fig. S10A,C), suggesting
a role for STING in the p62 phosphorylation and pro-
tein inclusion processes. However, under the CD-
HFD treatment, the effect of STING loss was not
detectable (Supporting Fig. S10F-H). Therefore, even
though the cGAS-STING pathway plays important
roles in activating TBK1 upon lipotoxic stimuli, other
types of metabolic insults such as choline deficiency
and liver damage can activate additional independent
signaling pathway(s) that can provoke activation of the
TBK1-p62 signaling.
Discussion
The hepatocyte protein inclusion is one of the most
prominent histopathological features of diseased hepa-
tocytes in fatty liver,(3-5,7-9) in addition to steatosis and
cell death. The association between fatty liver patholo-
gies and inclusion bodies has been known for around
100 years, and ubiquitinated proteins and p62/
SQSTM1 were more recently shown to be the major
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FIG. 6. Inhibition of TBK1 suppresses NASH-associated p62 phosphorylation and protein inclusion without alleviating hepatosteato-
sis and liver damage. (A-E) Four-month-old C57BL/6 male mice kept on CD-HFD for 2 months were subjected to daily adminis-
tration of vehicle (Con; 5% Tween-80 and 5% PEG-400; n 5 10) or BX795 (25 mg/kg body weight, intraperitoneal; n 5 5) for 10
days. LFD-kept mice (n 5 5) of the same age were used as a negative control. (A) Livers were subjected to solubility fractionation.
One percent Triton X-100-insoluble fractions were analyzed by immunoblotting (left panel) and immunoblotting quantification (right
panels). (B,D) Liver sections were subjected to p62 and F4/80 immunostaining, hematoxylin and eosin (H&E) staining, Oil Red O
(ORO) staining, and terminal deoxynucleotidyl transferase dUTP Nick-End Labeling (TUNEL) staining. Hematoxylin counterstain-
ing was used to visualize nuclei. Scale bars, 200 lm. Boxed areas are magnified in the insets. (C) Serum ALT levels were quantified.
(E) Relative F4/80 expression was quantified through RT-PCR. All data are shown as mean 6 SEM. NS, not statistically significant;
*P < 0.05; **P < 0.01; ***P < 0.001; Student t test). Arrowheads indicate the exact or nearest position of the protein molecular-
weight markers (kD).
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components.(3,8) Still, whether these p62 inclusions
indeed play a pathogenetic role, and the mechanisms
of how these inclusion bodies form during lipotoxic
injuries, largely remained elusive until very recently. In
addition to recent studies that showed the pathoge-
netic role for p62 inclusions during autophagy inhibi-
tion, NASH, and HCC,(12,37) our current study
provides a mechanism for how p62 protein inclusions
can form inside lipid-laden hepatocytes during fatty
liver and NASH.
We demonstrate here that SFA- or obesity-induced
lipotoxicity promotes protein inclusion formation
through activation of the TBK1 signaling pathway.
Also referred to as the xenophagy pathway, the TBK1
axis has been known to facilitate autophagic elimina-
tion of invading microorganisms in macrophages (Fig.
8C).(22) In this process, TBK1, activated by bacterially
derived lipopolysaccharide, cyclic dinucleotides, or
DNA, phosphorylates p62 at Ser403 and subsequently
promotes its association with ubiquitinated bacterial
proteins, forming bacteria-p62 aggregates that are des-
tined for autophagic degradation. Here, we showed
that the same pathway plays a distinct pathogenetic
role in hepatocytes during obesity-associated NASH.
Upon lipotoxic insults, TBK1 is activated by the
cGAS-STING pathway, as well as by unknown sig-
naling mediators (Fig. 8D). Activated TBK1 phos-
phorylates p62 at Ser403, promoting the formation of
ubiquitinated protein inclusions. Although this process
normally functions to prepare ubiquitinated proteins
for autophagic degradation, obesity and lipotoxic inju-
ries interfere with autophagic flux through an indepen-
dent mechanism.(13,15) Therefore, protein inclusions
that cannot be degraded by either autophagy or protea-
somal pathways accumulate and grow larger in size.
p62 phosphorylation and accumulation further up-
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FIG. 7. Inhibition of TBK1 suppresses liver fibrosis induced by NASH. (A-E) Mice described in Fig. 6 were also analyzed by the
following experiments. (A) Liver sections were subjected to Sirius Red staining and a-SMA immunostaining. Scale bars, 200 lm.
Boxed areas are magnified in the bottom panel. (B) Areas positive for Sirius Red (left panel) or a-SMA fluorescence intensity (right
panel) were quantified. (C,D) Total liver lysates were analyzed by immunoblotting (C) and immunoblotting quantification (D). (E)
Relative mRNA expression was quantified through RT-PCR. All data are shown as mean 6 SEM. *P < 0.05; **P < 0.01; ***P <
0.001 (Student t test). Arrowheads indicate the exact or nearest position of the protein molecular-weight markers (kD).
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regulates p62 expression through Nrf2-mediated posi-
tive feedback,(33) which aggravates autophagy overload
and malfunctioning. These results provide a mechanis-
tic explanation of how p62 inclusions form during lip-
otoxic injuries and fatty liver. Even though more
studies need to be done on how these inclusions are
mechanistically associated with other pathological fea-
tures of NASH, we believe that this study, delineating
the mechanisms of how lipotoxic injuries provoke p62
protein inclusions, is an important advance in the field
of NASH and fatty liver diseases.
Because p62 is known to regulate redox homeosta-
sis, nutrient signaling, and carcinogenic processes,(16)
lipotoxic p62 phosphorylation and accumulation may
play additional pathogenetic roles in fatty liver disease.
Indeed, our results indicate that TBK1 inhibition,
which suppresses p62 phosphorylation and accumula-
tion, can specifically restore liver ROS accumulation
and subsequent fibrotic pathologies in a NASH model
induced by CD-HFD. However, other NASH-
associated pathologies, such as hepatosteatosis, hepato-
cyte damage, and macrophage infiltration, were not
altered by TBK1 inhibition in this model. Interest-
ingly, recent studies of hepatocellular p62 indicated
that hepatocyte-specific p62 knockout mice, which do
not form hepatic protein inclusions, showed the exact
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FIG. 8. Inhibition of TBK1 suppresses hepatic oxidative stress during NASH. (A) Fresh frozen liver sections from mice described in
Fig. 6 were analyzed by DHE staining, which visualizes ROS. Scale bars, 200 lm. (B) DHE fluorescence intensity was quantified.
Data are shown as mean 6 SEM. ***P < 0.001 (Student t test). (C) During infection, TBK1-dependent p62 phosphorylation induces
aggregation of ubiquitinated microorganisms, making them better substrates for autophagy, which leads to quicker microorganism
elimination. (D) During obesity and NAFLD, lipotoxic activation of TBK1 signaling provokes the formation of p62-ubiquitin aggre-
gates. Because of autophagy defects, hepatocytes cannot efficiently eliminate these aggregates, leading to the formation of large protein
inclusions during NASH. These protein inclusions can provoke sublethal ROS accumulation, which can culminate in the development
of fibrosis during NASH. In addition, lipotoxicity may also increase TBK1 signaling in nonhepatocytes, such as hepatic stellate cells
and immune cells, which may contribute to the fibrotic pathologies. Question marks denote the mechanistic connections that still
need to be established by future investigations.
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same phenotype; p62 ablation suppressed liver ROS
and fibrosis without alleviating hepatosteatosis during
NASH.(12) Because both TBK1 inhibition and p62
ablation suppresses protein inclusion formation, oxida-
tive stress, and fibrosis, it is plausible that the protein
inclusions play a pathogenetic role in redox imbalance
and subsequent fibrotic progression. For instance,
aberrant accumulation of protein inclusions and subse-
quent block of autophagy can impair the clearance of
dysfunctional mitochondria that produce pathogenic
levels of ROS. However, the exact mechanism for how
p62 inclusions provoke a redox imbalance in the liver
during NASH was not provided by either the former
studies or the current study. Therefore, future investi-
gation should work toward extensively understanding
this potential mechanism. In addition, considering
that TBK1 has a well-established role in regulating
inflammatory signaling,(38) it is possible that the
observed effects on liver fibrosis were mediated
through p62-independent mechanisms in nonhepato-
cytes such as macrophages or hepatic stellate cells.
Although damaged hepatocytes are among the major
sources of ROS during NASH, other cell types, such
as immune cells, could also contribute to the ROS pro-
duction.(36) Therefore, even though it is likely that
hepatic protein inclusions are specific promoters of
liver fibrosis and that TBK1 is a central signaling com-
ponent for this NASH-promoting process, alternative
explanations are possible through the role of TBK1-
expressing nonhepatocytes (Fig. 8D).
Excessive p62 protein inclusions in NASH predis-
pose a patient to HCC progression, and HCC with
prominent p62 inclusions predicts a poor prognostic
outcome.(12,39,40) Therefore, the p62 protein inclusions
may also have a role in promoting liver cancer. Indeed,
recent animal studies established that the homeostatic
maintenance of p62 levels in liver tumors and tumor
microenvironments is important for suppressing hepa-
tocarcinogenesis.(12,16,33,41) Specifically, p62 accumula-
tion in hepatocytes promotes HCC development
during NASH,(12) whereas endogenous p62 in hepatic
stellate cells suppresses HCC by modulating the tumor
microenvironment.(41) Given that our results show that
obesity-activated TBK1 signaling plays a critical role
in producing p62 inclusion accumulation in hepato-
cytes during lipotoxicity, it may provide the molecular
conduit of how hypernutrition and obesity can pro-
mote NASH-associated development of HCC.(6)
It should be noted that pharmacological TBK1 inhi-
bition was recently shown to alleviate NAFLD and
insulin resistance in both humans and mice,(24,42)
which is likely to be mediated by the inflammation-
regulating role of TBK1 in adipose tissues and macro-
phages.(24,34,38) In addition to these well-established
roles in inflammation, our current study shows that
TBK1 also plays an important role for protein homeo-
stasis in hepatocytes through regulating p62 phosphor-
ylation. TBK1 inhibition and subsequent suppression
of hepatic protein inclusions might also contribute to
restoring liver redox homeostasis and attenuating
fibrotic disease progression. Therefore, further investi-
gation about how the TBK1 pathway is regulated by
lipotoxic insults and how TBK1 regulation in different
tissues affects various pathologies in NASH may bring
about a new paradigm for understanding NAFLD, as
well as other similar types of liver diseases that present
with the disruption of protein homeostasis.
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